Towards a better understanding of cancer and personalized medicine
Cancer remains one of the major causes of death and continues to require massive global research efforts. The ability to discover and validate more cancer-related protein biomarkers will be instrumental in addressing this huge healthcare challenge – paving the way for better understanding, diagnosis, and personalized treatment for cancer patients.
Our Oncology III panel is a high-throughput, multiplex immunoassay enabling analysis of 92 established and exploratory oncology-related protein biomarkers across 96 samples simultaneously. This high level of multiplexing is achieved without any compromise on data quality, thanks to our proprietary Proximity Extension Assay (PEA) technology. For optimal assay performance, each analyte in the panel has been validated in terms of sample material, specificity, precision, sensitivity, dynamic range, matrix effects and interference.
The panel comprises 92 human proteins that participate in biological mechanisms that are central to the initiation and progression of cancer, e.g. angiogenesis, cell communication, cellular metabolic processes, apoptosis, cell proliferation/differentiation etc. Many of the assays also address proteins that are defined as relevant for cancer according to DisGenNet, including multiple markers associated with carcinogenesis, tumor progression, solid tumors, and recurrent tumors. Some of the established cancer-related biomarkers in the new panel include: Cell surface A33 antigen, B-cell receptor CD22, Pro-neuropeptide Y, Allograft inflammatory factor 1 and Vascular endothelial growth factor receptor 1.
This panel provides a perfect complement to our Olink® ONCOLOGY II panel, enabling oncologists to measure 184 proteins in 2 dedicated panels. For the many researchers who take a wider approach to biomarker discovery, the panel is an important part of our extensive library of high-quality protein assays.
An overview of how the 92 biomarker assays in the panel are classified according to Biological Process, Disease Area, Tissue Expression and Protein Class (based on widely used public-access bioinformatic databases, including Uniprot, Human Protein Atlas, Gene Ontology (GO) and DisGeNET) can be seen in the charts below. These charts are interactive: click on a chart-bar or pie-segment to see the list of biomarkers in that classification. Each item in the list links to the detailed biomarker page with validation data.
A comprehensive list of all protein biomarkers that can be measured using the currently available Olink panels can be seen on the biomarker library page.
Note: A printable list of the biomarker assays available in this panel, as well as a full data validation document, can be downloaded from our Document download center >>
If you prefer not to run the assay yourself, let our experts here at Olink do this for you via our Analysis Service.
The biomarker pages linked to below include calibrator curves that show the performance of each assay with the estimated sensitivity and dynamic range parameters indicated. These curves are generated during the assay validation process using recombinant antigens, with data presented as Normalized Protein eXpression (NPX) values plotted against protein concentration (in pg/mL). Please note that when analyzing biological samples the data generated will be given in the form of relative quantification (NPX values) and cannot be converted to absolute protein concentrations. For more info about NPX measurements, please view the FAQ.